EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pregnane X receptor-mediated liver growth: a controlled clinical trial in healthy volunteers and identification of the role of AKT–MTOR pathway in mouse

Piia Lassila, Mikko Karpale, Outi Kummu, Aaron Stahl, Aki Käräjämäki, Eija Pääkkö, Helen Sophie Hammer, Albert Braeuning, Oliver Pötz, Markus Templin, Janne Hukkanen, Jukka Hakkola iD

Archives of Toxicology · 2026-12 · 100 (12) · 5513-5528

DOI: 10.1007/s00204-026-04526-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Toxicology, online erschienen am 26.08.2026. Verfasst von Piia Lassila und 11 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit of Biomedicine and Internal Medicine, Pharmacology and Toxicology, Biocenter Oulu, Medical Research Center Oulu, Oulu University Hospit…. Hauptthemen laut MEDLINE: Pregnane X Receptor, TOR Serine-Threonine Kinases, Liver, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Oulu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pregnane X receptor (PXR) is a nuclear receptor acting as a master xenobiotic receptor for many exogenous chemicals. Activation of PXR has been linked to liver growth in mice, usually via interaction with Yes-associated protein (YAP), but this adaptive response has not been observed in humans. We investigated the effect of human PXR agonist, rifampicin, on liver size in a controlled clinical trial in healthy volunteers. Moreover, we developed a novel protocol to reveal mechanisms of PXR-mediated liver growth in mice. One-week rifampicin treatment caused a 2.7% mean increase in liver volume-to-body weight ratio without affecting liver fat content in human volunteers (n=16). Pxr −/− mice were transduced with adenovirus carrying either murine PXR or green fluorescent protein and both groups were treated with pregnenolone−16α-carbonitrile (PCN) for 0 to 4 days. In this setup, activation of PXR with PCN significantly increased liver size in male mice already after 1-day PCN treatment and the liver growth was further enhanced after 4 days. No significant liver enlargement was observed in female mice. 4-day PCN treatment also improved glucose tolerance in the male mice. RNA-sequencing revealed upregulation of genes and pathways involved in proliferation. DigiWest protein profiling and immunoblotting revealed increased activity of AKT–mammalian target of rapamycin (MTOR) pathway in the male mice. In contrast, we did not observe YAP activation. Our results indicate that PXR activation induces liver growth and activates proliferative AKT–MTOR pathway in male mice and may also induce liver growth in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pregnane X ReceptorTOR Serine-Threonine KinasesLiverProto-Oncogene Proteins c-aktRifampinAnimalsHumansMaleFemaleAdultPregnenolone CarbonitrileSignal TransductionMice, KnockoutMiceAdaptor Proteins, Signal TransducingReceptors, SteroidYoung AdultMice, Inbred C57BLYAP-Signaling ProteinsHealthy VolunteersPhosphoproteinsOrgan Size

Stichwörter der Autor:innen

AKTLiver hypertrophyMTORPCNPXRRifampicin

Substanzen

Pregnane X ReceptorTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPregnenolone CarbonitrileRifampinMTOR protein, humanmTOR protein, mouseAdaptor Proteins, Signal TransducingReceptors, SteroidYAP-Signaling Proteins

Autor:innen und Institutionen

  • Research Unit of Biomedicine and Internal Medicine, Pharmacology and Toxicology, Biocenter Oulu, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, POB 5000, 90014, Oulu, Finland.
  • NMI Natural and Medical Sciences Institute at the University Tübingen, Reutlingen, Germany.
  • Department of Internal Medicine, Vaasa Central Hospital, Vaasa, Finland.
  • Department of Diagnostic Radiology, Oulu University Hospital, Oulu, Finland.
  • SIGNATOPE GmbH, Reutlingen, Germany.
  • Department of Food Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.

ORCID-Profile: Jukka Hakkola

Förderung

  • University of Oulu

Zitieren

APA

Lassila, P., Karpale, M., Kummu, O., Stahl, A., Käräjämäki, A., Pääkkö, E., Hammer, H. S., Braeuning, A., Pötz, O., Templin, M., Hukkanen, J., & Hakkola, J. (2026). Pregnane X receptor-mediated liver growth: a controlled clinical trial in healthy volunteers and identification of the role of AKT–MTOR pathway in mouse. Archives of Toxicology, 100(12), 5513-5528. https://doi.org/10.1007/s00204-026-04526-5

Vancouver

Lassila P, Karpale M, Kummu O, Stahl A, Käräjämäki A, Pääkkö E, et al. Pregnane X receptor-mediated liver growth: a controlled clinical trial in healthy volunteers and identification of the role of AKT–MTOR pathway in mouse. Archives of Toxicology. 2026;100(12):5513-5528. doi:10.1007/s00204-026-04526-5

BibTeX
@article{Lassila2026,
  author = {Lassila, Piia and Karpale, Mikko and Kummu, Outi and Stahl, Aaron and Käräjämäki, Aki and Pääkkö, Eija and Hammer, Helen Sophie and Braeuning, Albert and Pötz, Oliver and Templin, Markus and Hukkanen, Janne and Hakkola, Jukka},
  title = {Pregnane X receptor-mediated liver growth: a controlled clinical trial in healthy volunteers and identification of the role of AKT–MTOR pathway in mouse},
  journal = {Archives of Toxicology},
  year = {2026},
  volume = {100},
  number = {12},
  pages = {5513--5528},
  doi = {10.1007/s00204-026-04526-5}
}
Kostenlos starten →